Maritide shows efficacy comparable to Ozempic and advances for phase 3 study expecting even better results
Californian pharmacist Amgen revealed promising results of the phase II clinical trial of her new drug to obesitythe maritide.
In just one monthly application, participants lost between 12.3% and 16.2% of body weight over a year – performance comparable to Ozepic, administered weekly.
The study on the drug was published in the magazine The New England Journal of Medicine.
Study Details
- The study involved 592 adults with BMI over 30, including people with type 2 diabetes.
- The group that received Maritide had significantly higher weight losses than the Placebo group, which lost only 2.5% on average.
- Important to highlight: participants had not yet reached a weight loss plateau, which suggests potential for even better results with prolonged use.
Read more:
How the medicine acts
Maritide combines two mechanisms: a GLP-1 receptor agonist, which increases satiety (such as Ozepic), and a GIP receptor antagonist, which blocks signals linked to weight gain.
Its prolonged action formula allows monthly application, which may benefit patients in regions with less access to medical care.
Gastrointestinal side effects were observed, but diminished with lower or progressive doses. AMGEN is now preparing for a 72 -week phase III test, as well as investigating the use of the drug in patients with heart disease and sleep apnea.
Collaboration for the digital look
Leandro Criscuolo is a journalist graduated from Cásper Líbero College. He has worked as Copywriter, digital marketing analyst and social networking manager. Currently, he writes for the digital look.
